Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06162897 · ClinicalTrials.gov registry record · NA
Case Management Dyad
A NA study of HIV and Pre-exposure Prophylaxis, sponsored by University of Chicago.
- Recruiting
- Registry status
- NA
- Development phase
- 180
- Enrollment target
- 1
- Study location
NCT06162897: Recruiting NA study of HIV and Pre-exposure Prophylaxis, sponsored by University of Chicago.
NCT06162897 is a NA study of HIV and Pre-exposure Prophylaxis that is actively recruiting participants, run by University of Chicago. The registered enrollment target is 180 participants, below the 439-participant average among 303 other HIV trials with a reported enrollment target (59% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06162897, a NA study of HIV and Pre-exposure Prophylaxis, is actively recruiting participants, sponsored by University of Chicago.
- RECRUITING
- Registry status
- NA
- Development phase
- 180 participants
- Enrollment target
- 1
- Study location
Study Summary
The overall goal of this study is to test whether dyadic and focused case management will (1) improve financial wellbeing, (2) improve access to food, (3) increase linkage and retention rates for individuals living with HIV or those taking PrEP (PrEP persistence), and (4) increase the proportion of individuals living with HIV who are virally suppressed (viral suppression) when compared to routine Ryan White Non-Medical Case Management.
Primary Outcome
Proportion of subjects who report improved financial wellbeing (e.g. consistent income, ability to pay bills).
Conditions Studied
Interventions
- BEHAVIORAL Dyadic Case Management
Study Locations (1)
Illinois
- University of Chicago - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 180 participants |
| Start Date | 2022-09-09 |
| Est. Completion | 2027-06-30 |
| Phase | NA |
What NCT06162897 shows while recruiting
NCT06162897 is an interventional study that assigns participants to a tested intervention. The registered 180 participants enrollment target is mid-sized for trials with a published cap, below the 439-participant average among 303 other HIV trials with a reported enrollment target (59% lower).
The record links to 3 conditions, with HIV appearing as the primary indexed condition, and to 1 intervention - of which Dyadic Case Management is the first listed.
NCT06162897 reports a single indexed study location in Illinois.
Frequently Asked Questions
What is clinical trial NCT06162897 about?
NCT06162897 is a clinical study titled "Case Management Dyad". The overall goal of this study is to test whether dyadic and focused case management will (1) improve financial wellbeing, (2) improve access to food, (3) increase linkage and retention rates for individuals living with HIV or those taking PrEP (PrEP persistence), and (4) increase the proportion of ...
What is the current status of trial NCT06162897?
This trial is currently recruiting. It is a NA study. The enrollment target is 180 participants. The study started on 2022-09-09. Estimated completion is 2027-06-30.
What conditions does trial NCT06162897 study?
This clinical trial studies the following conditions: HIV, Pre-exposure Prophylaxis, Case Management.
What interventions are being tested in trial NCT06162897?
The interventions under investigation include: Dyadic Case Management (BEHAVIORAL).
Who is sponsoring clinical trial NCT06162897?
This trial is sponsored by University of Chicago, which has 796 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06162897 being conducted?
This trial has 1 study location across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for HIV
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06162897's enrollment target sits among peer trials
180 120th of 303 higher than 182 of 303 other HIV trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other HIV trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Text Education About Cardiovascular Health and HIV (TEACH-HIV)
RECRUITING · NA
-
1MoreStep: An Intervention to Increase HIV Care Engagement and Reduce Intimate Partner Violence Among Black Women Living With HIV
RECRUITING · NA
-
Implementation Trial to Evaluate a Population Health Combination Intervention to Meet HIV Testing, Linkage, and Viral Suppression Goals in Alabama
RECRUITING · NA
-
ACCESS: Accelerating Cervical Cancer Elimination Through the Integration of Screen-and-treat Services
RECRUITING · NA
-
Assessing Peer Support for Physical Activity in Women With HIV and Hypertension
RECRUITING · NA
-
Open Trial of Trauma-focused Psychodynamic Psychotherapy for People Living With HIV and PTSD
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01558804 · 180 participants
GRoup A StrePtococcus
- NCT02932176 · 180 participants
Machine Learning for Handheld Vascular Studies
- NCT03384563 · 180 participants · Phase 4
Effect of Dexmedetomidine on the Minimum Alveolar Concentration of Sevoflurane
- NCT03423628 · 180 participants · Phase 1
A Study to Assess the Safety and Tolerability of AZD1390 Given With Radiation Therapy in Patients With Brain Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI